新浪登录
腾讯登录无创产前诊断新型公司Singlera同耶鲁大学合作开展新型NIPT临床试验
| 导读 | 近日，无创产前诊断新兴公司Singlera Genomics同耶鲁大学的科学家们合作开展了一项临床试验，旨在评估Singlera公司用于进行染色体非整倍性及胎儿DNA碎片测定的新型无创产前诊断技术的效力。 |
近日，无创产前诊断新兴公司Singlera Genomics同耶鲁大学的科学家们合作开展了一项临床试验，旨在评估Singlera公司用于进行染色体非整倍性及胎儿DNA碎片测定的新型无创产前诊断技术的效力。
来自约翰霍普金斯大学的研究者Yuan Gao及加利福尼亚大学的研究者Kun Zhang于2014年6月在加利福尼亚州拉荷亚共同创建了Singlera Genomics公司，该公司拥有多项专利技术，而这些技术都是在Zhang的实验室开发的，而且都用于进行专用的NIPT检测，周期大约为1-2天。来自耶鲁大学的研究者Michael Paidas表示，他们将在临床试验中对Singlera公司的新型检测技术进行评估，据Singlera公司介绍，相比其它的NIPT技术而言，目前这种新型技术的优势在于其可以同时对胎儿的DNA碎片进行测定，而胎儿DNA碎片在高体重指数的女性机体中水平往往较低。
研究者Paidas在一项声明中指出，对体重指数增加的女性进行一项可靠的筛查将会是一项变革性的技术革新，而且还会明显降低在人群中进行的侵入性检测。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，转载请点击授权获取授权
转化医学网推荐的新闻阅读：
Singlera Genomics, Yale Partner on NIPT Clinical Trial
NEW YORK (GenomeWeb) – Noninvasive prenatal testing startup Singlera Genomics has partnered on a clinical trial with researchers at Yale University to evaluate Singlera's technology for noninvasive prenatal testing of chromosomal aneuploidy and fetal DNA fraction measurement.
Yuan Gao from Johns Hopkins University and Kun Zhang from the University of California, San Diego cofounded La Jolla, California-based Singlera in June 2014. The company has exclusively licensed several technologies developed in Zhang's UCSD laboratory for its proprietary NIPT, which has a turnaround time of one to two days, the company said.
Researchers from Yale, led by Michael Paidas, professor and vice chair of obstetrics, will evaluate Singlera's test in a clinical trial. According to the company, an advantage of the test compared to other NIPTs is that it simultaneously measures fetal DNA fraction, which has been observed to be lower in women with a higher body mass index.
"Having a reliable screen for patients with increased body mass index would be transformative and significantly decrease invasive testing in this population," Paidas said in a statement.
还没有人评论，赶快抢个沙发